SUMMARY, EXPLANATION AND LIMITATIONS:
CD99 (p30/32 MIC2, MIC2 or E2) is a transmembrane glycoprotein of 32 kDa. The CD99 antigen was initially described as a specific antigen derived lymphomas peripheral T lymphocytes and thymocytes. In peripheral blood, as well as T cells, NK cells and monocytes expressing high levels of CD99, which on the contrary is virtually undetectable on B lymphocytes and granulocytes. Other normal cells are positive for CD99 in the islets of Langerhans of the pancreas, ovarian granulosa, Sertoli, Leydig and the ependymal cells. The functions of CD99 are not well known, having linked this protein with the induction of apoptosis and activation of the TCR and HLA molecules in thymocytes during processing immune cell adhesion between T lymphocytes (anti-CD99 antibody blocks the spontaneous formation rosettes with ram erythrocytes by T lymphocytes) and has recently been reported that stimulation of CD99 by its specific antibody leads to differential activation of MAP kinase family of cytoskeletal rearrangement and cell aggregation.
Immunogen: Recombinant full length human CD99 protein.
Staining pattern: Cell membrane.
Positive control: Tissue sample from pancreas, testicle.
This antibody is designed for the specific localization of human CD99 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
Under proper conditions of fixation and antigen unmasking, CD99 is an antigen expressed in almost 100% of Ewing sarcomas and peripheral primitive neuroectodermal tumors (PNET). However, despite such a high sensitivity labeling is not exclusively specific to this group of tumors often been described positivity in T lymphoblastic lymphomas and peripheral T-cell lymphomas, gastrointestinal stromal tumors, fibrous tumor primitive and virtually all neoplasms arising of tissues that normally express CD99.